Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125004) titled 'A Prospective Randomized Controlled Trial of IL-1 Monoclonal Antibody for Reducing Arthritis Flare-ups in Gout Patients with Concomitant Chronic Kidney Disease' on May 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University First Hospital
Condition:
Gouty arthritis
Intervention:
Anti-IL-1ß monoclonal antibody group:Voxinqibizumab 200mg was administered subcutaneously
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-20
Target Sample Size: Anti-IL-1ß monoclonal antibody group:16;Compound Betamethasone group:16;
Countries ...